Patient Case: A 67-Year-Old, BCMA-Naïve, Woman with Relapsed Refractory Multiple Myeloma
Panelists discuss how to tailor treatment strategies for a 67-year-old, BCMA-naïve woman with relapsed/refractory multiple myeloma, weighing the potential benefits of BCMA-targeted therapies against other available options in the context of her specific clinical presentation.
EP: 1.Treatment Strategies in Relapsed Refractory Multiple Myeloma
EP: 2.Ide-Cel: Real-World Outcomes for Relapsed Refractory Multiple Myeloma
EP: 3.KarMMa-3: Ide-cel vs Standard of Care Therapies in Relapsed Refractory Multiple Myeloma
EP: 4.CARTITUDE-4: Cilta-cel vs Standard of Care Therapies in Relapsed Refractory Multiple Myeloma
EP: 5.Patient Case: A 68-Year-Old Woman with Triple Class Exposed Relapsed Refractory Multiple Myeloma
EP: 6.Patient Case: A 67-Year-Old, BCMA-Naïve, Woman with Relapsed Refractory Multiple Myeloma
EP: 7.Sequencing Therapies for Relapsed Refractory Multiple Myeloma: Bispecifics or CAR T-cell Therapy
EP: 8.Bispecific Selection in BCMA-failed Therapy for Relapsed Refractory Multiple Myeloma
EP: 9.Use of CAR T-cell Therapy in Earlier Lines in Relapsed Refractory Multiple Myeloma
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
